Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Downgraded by Zacks Investment Research to “Sell”

Share on StockTwits

Zacks Investment Research downgraded shares of Corindus Vascular Robotics (NYSEAMERICAN:CVRS) from a hold rating to a sell rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Separately, Cowen lowered shares of Corindus Vascular Robotics from an outperform rating to a market perform rating and raised their price objective for the company from $4.00 to $4.28 in a report on Thursday, August 8th.

Shares of CVRS stock opened at $4.27 on Tuesday. Corindus Vascular Robotics has a 52 week low of $0.78 and a 52 week high of $4.30.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last issued its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $4.58 million for the quarter, compared to the consensus estimate of $4.10 million.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Corindus Vascular Robotics during the 4th quarter worth $36,000. Virtu Financial LLC raised its stake in Corindus Vascular Robotics by 128.4% during the 1st quarter. Virtu Financial LLC now owns 173,312 shares of the medical equipment provider’s stock worth $301,000 after acquiring an additional 97,445 shares in the last quarter. First Republic Investment Management Inc. acquired a new stake in Corindus Vascular Robotics during the 1st quarter worth $122,000. Independent Advisor Alliance acquired a new stake in Corindus Vascular Robotics during the 1st quarter worth $75,000. Finally, EAM Global Investors LLC acquired a new stake in Corindus Vascular Robotics during the 1st quarter worth $1,024,000.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.

See Also: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Corindus Vascular Robotics  Downgraded by Zacks Investment Research to “Sell”
Corindus Vascular Robotics Downgraded by Zacks Investment Research to “Sell”
Craig Hallum Lowers eMagin  to Hold
Craig Hallum Lowers eMagin to Hold
Zacks Investment Research Upgrades Saipem  to Buy
Zacks Investment Research Upgrades Saipem to Buy
Castle Brands  Lowered to Hold at Zacks Investment Research
Castle Brands Lowered to Hold at Zacks Investment Research
Zacks Investment Research Lowers Rentokil Initial  to Sell
Zacks Investment Research Lowers Rentokil Initial to Sell
Zacks Investment Research Upgrades SThree  to Hold
Zacks Investment Research Upgrades SThree to Hold


© 2006-2019 Ticker Report